Potential risk factors for SARS-CoV-2 infection in patients with rheumatic diseases
Medication for patients with rheumatic diseases #
Surgery
Patients with RD and fever*
# Concerning glucocorticoids, immunosuppressants, csDAMRDs, bDMARDs and JAK inhibitors, the balance of safety and efficacy in viral infection as well as pulmonary inflammation remains unclear.
We have been alerted to fraudulent emails sent from the following addresses, falsely claiming to be from the APLAR President and APLAR President-Elect:
• presidetn2024@gmail.com
• persidentcochair@gmail.com
🔴 Please note: These emails are not from APLAR and are an attempt to impersonate our leadership.
We strongly advise all members to:
• 🚫 Do not reply or engage with the sender
• 📎 Do not click on any links or open attachments
• 🗑️ Delete the email immediately
• 🛡️ Report it as spam or phishing to your email provider
✅ Official APLAR communications will always come from verified @aplar.org email addresses.
If you have any doubts or concerns, please contact:
📧 secretariat@aplar.org | ☎️ (65) 6774 5201
Thank you for staying alert.
— APLAR Secretariat